Isabelle Genvresse
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 23, 2024
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 01, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 07, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 02, 2020
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 29, 2020
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
Journal: Targeted oncology
Published: October 27, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
Journal: Leukemia
Published: June 23, 2020
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
Journal: Targeted oncology
Published: April 22, 2020
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Journal: Molecular cancer therapeutics
Published: May 02, 2019
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Journal: British journal of cancer
Published: August 08, 2017
Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.
Journal: Cancer chemotherapy and pharmacology
Published: June 13, 2017
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 30, 2016
Showing 1-12 of 12
Last Updated: 09/26/2026